Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Albusomatropin - Teva Pharmaceutical Industries

Next Previous
X
Search
Drug Profile

Albusomatropin - Teva Pharmaceutical Industries

Alternative Names: Albumin/somatropin fusion protein; Albutropin; Human Growth Hormone Therapy - Teva; Somatropin/albumin fusion protein; TV-1106

Latest Information Update: 24 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CoGenesys
  • Developer Teva Pharmaceutical Industries
  • Class Growth hormones
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Somatotropin deficiency

Most Recent Events

  • 10 May 2016 Teva Pharmaceutical terminates a phase II trial in Somatotropin deficiency (In children, Treatment-naive) in Bulgaria, Belarus, Czech Republic, Greece, Hungary, Romania, Russia, Ukraine, Serbia, Spain, Georgia, Poland, Israel and Turkey (NCT02092077)
  • 01 Apr 2016 Teva terminates a phase III trial in Somatotropin deficiency (In adults) in USA (SC) (NCT02410356)
  • 01 Apr 2016 Teva terminates a phase III trial in Somatotropin deficiency (Treatment-experienced but not on rhGH treatment within the past 12 months, In adults) in USA (SC) (NCT02410343)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top